Resverlogix Corp.

Resverlogix Corp.

October 07, 2005 13:00 ET

Resverlogix to Present at BioPartnering Europe

CALGARY, ALBERTA--(CCNMatthews - Oct. 7, 2005) - Resverlogix Corp. (TSX:RVX), announced today that senior management of the company; Donald J. McCaffrey, Dr. Jan Johansson and Kenneth Lebioda, will present at the 13th annual BioPartnering Europe to be held in London, England from October 9th to 11th, 2005. Over 850 delegates from Europe, the US and Asia attracting key decision makers from the biotechnology, pharmaceutical and financial industries are registered to attend this premier biotech partnering conference in Europe.

In other news, Resverlogix Corp. granted 450,000 stock options to its directors and an officer at an exercise price of $6.25, vesting over a period of 36 months and valid for a period of five years. This is the first granting of options to the directors since their initial election to the Board in April 2003.

About Resverlogix Corp.

NEXVAS™ Technology: The primary focus for Resverlogix is the development of new technology designed to control cholesterol related diseases such as atherosclerosis (the buildup of plaque in the arteries). Existing drugs control the level of LDL ("bad cholesterol") in the body and have only illustrated the slowing of atherosclerosis. Resverlogix's NEXVAS™ program is developing proprietary technology that stimulates the body to produce ApoA1 protein, the primary component of HDL, which results in increased levels of HDL ("good cholesterol"). ApoA1/HDL has been proven to not just arrest but reverse atherosclerosis by reducing existing cholesterol deposits. Activating the body to enhance ApoA1 levels is the simplest physiological or natural approach to regulating HDL.

Cardiovascular disease is the leading cause of death in industrialized countries. The drugs that are currently used to control cholesterol can only slow the progress of atherosclerosis, and yet they are the biggest selling drugs in the world with a combined market of some U.S. $30 billion annually. Resverlogix's ApoA1 technology has the potential to capture and expand much of this market.

For a more detailed explanation about NEXVAS™ technology, please access the animation on the company website at

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information